|| Checking for direct PDF access through Ovid
Nintedanib (Ofev®) is an important new option for the treatment of idiopathic pulmonary fibrosis (IPF). It inhibits receptor tyrosine kinases implicated in the pathogenesis of IPF. In the well-designed INPULSIS-1 and -2 trials in patients with IPF, nintedanib significantly reduced the decline in forced vital capacity versus placebo, indicating a slowing of disease progression. The time to first acute exacerbation was significantly increased with nintedanib in INPULSIS-2, but not in INPULSIS-1, and significantly less deterioration in health-related quality of life was seen with nintedanib in INPULSIS-2, but not in INPULSIS-1. Nintedanib had an acceptable tolerability profile in patients with IPF; gastrointestinal adverse events (in particular diarrhoea) were reported most commonly.